News
NVSEF
127.10
-6.34%
-8.60
Weekly Report: what happened at NVSEF last week (1103-1107)?
Weekly Report · 2d ago
U.S. launches pilot payment model to bring MFN pricing to Medicaid
Seeking Alpha · 5d ago
Weekly Report: what happened at NVSEF last week (1027-1031)?
Weekly Report · 11/03 09:30
Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Seeking Alpha · 11/01 19:15
VYMI: Foreign 4.3% Dividend Yield Made Cheap And Simple
Seeking Alpha · 10/31 20:56
PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing
Seeking Alpha · 10/29 21:50
Earnings Snapshot: Novartis Q3 tops revenue estimates, but misses on EPS; reaffirms FY outlook
Seeking Alpha · 10/28 08:42
Novartis reports mixed Q3 results; reaffirms FY25 outlook
Seeking Alpha · 10/28 06:26
S&P Futures Muted After Record Rally, FOMC Meeting and Earnings on Tap
Barchart · 10/28 05:16
Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats
Seeking Alpha · 10/27 21:08
Weekly Report: what happened at NVSEF last week (1020-1024)?
Weekly Report · 10/27 09:32
Novartis to buy Avidity Biosciences in $12B deal to boost rare disease pipeline
Seeking Alpha · 10/26 18:33
Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share
Seeking Alpha · 10/26 15:05
Eli Lilly: Is Another Monster Quarter Coming
Seeking Alpha · 10/26 12:15
Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Seeking Alpha · 10/22 20:11
Celcuity: Updated Gedatolisib Data Bodes Well For Mutant-Type Cohort Results
Seeking Alpha · 10/21 21:41
Weekly Report: what happened at NVSEF last week (1013-1017)?
Weekly Report · 10/20 09:31
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Seeking Alpha · 10/18 13:30
Novartis: Assessing The Impact Of Entresto Generics
Seeking Alpha · 10/16 17:23
Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again
Seeking Alpha · 10/14 12:58
More
Webull provides a variety of real-time NVSEF stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVSEF
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.